PT  - JOURNAL ARTICLE
AU  - Xu Wang
AU  - Isabelle M. Bennink
AU  - Kevin M. Veen
AU  - Pieter C. van de Woestijne
AU  - Carlijn C. E. M. van der Ven
AU  - Ad J. J. C. Bogers
AU  - Eleni-Rosalina Andrinopoulou
AU  - Wim. A. Helbing
AU  - Johanna J.M. Takkenberg
TI  - RVOT Reconstruction in d-Transposition of the Great Arteries with Ventricular Septal Defect and Pulmonary Obstruction: Male-Female Differences in Clinical and Homograft Function
AID  - 10.1101/2023.10.18.23297234
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.10.18.23297234
4099  - http://medrxiv.org/content/early/2023/10/19/2023.10.18.23297234.short
4100  - http://medrxiv.org/content/early/2023/10/19/2023.10.18.23297234.full
AB  - Background This study investigated male-female differences in clinical and homograft outcomes in dextro-transposition of the great arteries (d-TGA) patients, with ventricular septal defect (VSD) and pulmonary stenosis/atresia (PS/PA), who underwent right ventricular outflow tract (RVOT) reconstruction with a homograft.Methods All d-TGA with VSD and PS/PA patients receiving a homograft for RVOT reconstruction at our center from 1986 to 2021 were included. Time-to-event analyses were used for time-related clinical outcomes and mixed-effects models to characterize homograft function.Results Twenty-four patients (16 males) in whom 38 homografts were implanted over time were included. Median age at the first homograft implantation was 2.56 years [IQR: 1.26-11.31] and 2.06 years [IQR: 1.28-8.13] for males and females. Two early death (both males) and five late deaths (2 males) were observed. Twenty-two RVOT reinterventions (19/3 in males/females) occurred in follow-up (males/females:345.72/173.35 patient-years). The 10-year survival probability was 87.5% (95% CI: 67.3-100) for females and 87.1% (95% CI: 71.8-100) for males. Freedom from RVOT reintervention at 10-year was 87.5% (95% CI: 67.3-100) for females and 64.9% (95% CI: 47.9-88.0) for males. RVOT peak gradient increase rate was associated with body growth rate (7.27 [95% CI: 2.08-12.45], P=0.0133).Conclusions Substantial male-female differences in clinical and homograft outcomes were found in d-TGA with VSD and PS/PA patients receiving a homograft for RVOT reconstruction. Male patients had a higher RVOT reintervention rate and faster progression to homograft stenotic failure compared to females. Oversized homografts might benefit children for the strong association between rates of homograft stenosis and body growth.Clinical PerspectiveWhat is new? Male patients diagnosed with d-TGA, VSD, and PS/PA demonstrated a significantly higher rate of RVOT homograft reinterventions and a more rapid progression toward homograft stenotic failure when compared with their female counterparts.The male-female differences in clinical outcomes and homograft function may be attributed, in part, to the faster body growth observed in male children, especially given the strong association between rates of homograft stenosis and body growth.What are the clinical implications? For rapidly growing young children, opting for a suitably oversized homograft might serve as a more effective solution in reducing the rate of homograft stenotic failure.By exploring the relationship between homograft stenosis rate and individual body growth rate for each child, a personalized approach can be adopted during the homograft selection process, optimizing the sizing strategy for a better clinical outcome.Competing Interest StatementThe authors have declared no competing interest.Clinical Trialit is not a clinical trialFunding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The medical ethics committee (METC) of the Erasmus University Medical Center reviewed and approved this study (MEC-2012-477).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Not ApplicableThe data that support the findings of this study are available on request from the corresponding author, JJMT. The data are not publicly available due to the containing information that could compromise the privacy of research participants.